PMID- 21547676
OWN - NLM
STAT- MEDLINE
DCOM- 20110907
LR  - 20110506
IS  - 1976-3786 (Electronic)
IS  - 0253-6269 (Linking)
VI  - 34
IP  - 3
DP  - 2011 Mar
TI  - Therapeutic and cost effectiveness of proton pump inhibitor regimens for 
      idiopathic or drug-induced peptic ulcer complication.
PG  - 443-9
LID - 10.1007/s12272-011-0312-z [doi]
AB  - Peptic ulcer (PU) disease has a high rate of occurrence and recurrence in Korean 
      and the selection of drug for treatment is diverse. In this study, the 
      therapeutical effectiveness of regimens including proton pump inhibitors (PPI) 
      was compared with the single PPI therapy. The clinical data were collected from 
      1,658 patients having idiopathic or drug-induced PU complication from a Medical 
      Center in Daegu, Korea, and analyzed retrospectively based on the results of 
      endoscopic examination, the drug history and the therapeutic cost depending on 
      drugs used. The comparison of complete healing rate and recurrence rate showed no 
      significant differences between the single PPI groups and the combination group 
      with antacids, prokinetic agent or mucosa protectants. However, the combination 
      therapy of PPI with mucosa protectants gave a slightly better therapeutic outcome 
      than single PPI treatment in gastric ulcer patients. Comparatively, the 
      combination of PPI with antacids significantly reduced the therapeutic 
      effectiveness in duodenal ulcer patients. The analysis of cost-based therapeutic 
      effectiveness reveals that any economic benefits in PU treatment were not gained 
      by the combination of other class of ulcer drugs. Even though the rapidity of 
      healing rate was not considered, it can be concluded that the PPI combination 
      therapy might be not desirable in PU treatment. Particularly triplet or quartet 
      combination therapy in PPI regimen was absolutely economically ineffective 
      therapy in spite of the increase of medication costs.
FAU - Nam, Doo Hyun
AU  - Nam DH
AD  - Graduate School of Clinical Pharmacy, Yeungnam University, Daegu, Korea.
FAU - Park, So Young
AU  - Park SY
FAU - Park, Jong Min
AU  - Park JM
FAU - Kim, Sung Chull
AU  - Kim SC
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110506
PL  - Korea (South)
TA  - Arch Pharm Res
JT  - Archives of pharmacal research
JID - 8000036
RN  - 0 (Antacids)
RN  - 0 (Anti-Ulcer Agents)
RN  - 0 (Proton Pump Inhibitors)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antacids/administration & dosage/economics/therapeutic use
MH  - Anti-Ulcer Agents/administration & dosage/economics/therapeutic use
MH  - Cost-Benefit Analysis
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Peptic Ulcer/*complications/*drug therapy/prevention & control
MH  - Proton Pump Inhibitors/administration & dosage/*economics/*therapeutic use
MH  - Recurrence
MH  - Republic of Korea
MH  - Retrospective Studies
MH  - Treatment Outcome
EDAT- 2011/05/07 06:00
MHDA- 2011/09/08 06:00
CRDT- 2011/05/07 06:00
PHST- 2010/07/19 00:00 [received]
PHST- 2010/12/12 00:00 [accepted]
PHST- 2010/11/20 00:00 [revised]
PHST- 2011/05/07 06:00 [entrez]
PHST- 2011/05/07 06:00 [pubmed]
PHST- 2011/09/08 06:00 [medline]
AID - 10.1007/s12272-011-0312-z [doi]
PST - ppublish
SO  - Arch Pharm Res. 2011 Mar;34(3):443-9. doi: 10.1007/s12272-011-0312-z. Epub 2011 
      May 6.